Neximmune announces 1-for-25 reverse stock split

Gaithersburg, md., oct. 18, 2023 (globe newswire) -- neximmune, inc. (nasdaq: nexi) (the “company”) a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific t cells in oncology, autoimmune and infectious diseases, today announced that the board of directors and stockholders of the company approved a 1-for-25 reverse stock split of the company's common stock at a special meeting of the company held on october 17, 2023. the reverse stock split will take effect after the close of trading on the nasdaq capital market at 5:00 p.m. eastern time, on wednesday, october 18, 2023. the company's common stock will open for trading under a new cusip number 65344d 208 on the nasdaq capital market on october 19, 2023, on a split-adjusted basis under the current ticker symbol "nexi." the reverse stock split is intended to increase the per share trading price of the company's common stock to enable the company to regain compliance with the minimum bid price requirement for continued listing on the nasdaq capital market.
NEXI Ratings Summary
NEXI Quant Ranking